Tesaro winds up for FDA pitch as PARP ri­vals race to the fin­ish line

Armed with fast-track sta­tus from the FDA, Waltham, MA-based Tesaro $TSRO has got the ball rolling on its close­ly-watched reg­u­la­to­ry fil­ing for ni­ra­parib, one of the lead­ing PARP in­hibitors in late-stage de­vel­op­ment. The biotech has be­gun a rolling sub­mis­sion at the FDA for its drug as sev­er­al com­peti­tors line up to vie for the lead.

The next big step at Tesaro will be out­lin­ing the da­ta from the Phase III study of this drug. And what we know so far is promis­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER